Patents by Inventor Elizabeth Jane Thomas

Elizabeth Jane Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF METTL3
    Publication number: 20240101589
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: W—X—Y—Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: October 7, 2021
    Publication date: March 28, 2024
    Inventors: DAVID JAMES HARDICK, Wesley Peter Blackaby, Elizabeth Jane Thomas, Frederick Arthur Brookfield, Jon Shepherd, Christian Bubert, Mark Peter Ridgill
  • METTL3 INHIBITORY COMPOUNDS
    Publication number: 20230391770
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: October 5, 2021
    Publication date: December 7, 2023
    Inventors: David James Hardick, Wesley Peter Blackaby, Elizabeth Jane Thomas, Frederick Arthur Brookfield, Jon Shepherd, Christian Bubert, Mark Peter Ridgill
  • Polyheterocyclic compounds as METTL3 inhibitors
    Patent number: 11725010
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: August 15, 2023
    Assignee: Storm Therapeutics Limited
    Inventors: Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • METTL3 INHIBITORY COMPOUNDS
    Publication number: 20230085408
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z5 (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity 10 is implicated.
    Type: Application
    Filed: April 3, 2020
    Publication date: March 16, 2023
    Inventors: Wesley Peter BLACKABY, David James HARDICK, Elizabeth Jane THOMAS, Frederick Arthur BROOKFIELD, Christian BUBERT, Jon SHEPHERD, Mark Peter RIDGILL
  • POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS
    Publication number: 20230002378
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Application
    Filed: July 29, 2022
    Publication date: January 5, 2023
    Inventors: Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY
    Publication number: 20220370453
    Abstract: The present invention relates to compounds that function as inhibitors and/or degraders of BCDIN3D activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCDIN3D activity is implicated.
    Type: Application
    Filed: June 19, 2020
    Publication date: November 24, 2022
    Inventors: Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Lisa Marie Frost, Frederick Arthur Brookfield, Boris Aillard